Background: The introduction of direct oral anticoagulants (DOAC) has resulted in a paradigm shift in the management of venous thromboembolism (VTE). We evaluate the impact of the transition to DOAC, over the last decade, on overall VTE clinical outcomes including in first unprovoked major VTEs.
Method: A retrospective analysis of all VTE admissions in non-cancer patients from January 2011 to December 2020 at Northern Health, Victoria, Australia. "Warfarin era" included events that occurred between January 2011 and December 2014 and "DOAC era" from January 2016.
Results: There were 2687 cases involving 2508 patients (45.9 % males; median age 63 years). 98 % were symptomatic and 1261 events (47 %) were unprovoked. 1003 events occurred during the warfarin era (79 % warfarin, 6 % DOAC) and 1479 during the DOAC era (18 % warfarin, 70 % DOAC). While recurrent thrombosis during the acute phase of treatment was comparable, there were fewer recurrences during the long-term preventative phase of treatment in the DOAC era compared to warfarin era (HR 0.602, 95 % CI: 0.393-0.924, p0.020). Clinically significant bleeding events were lower in the DOAC era (HR 0.623, 95 % CI: 0.395-0.985, p = 0.043). A subanalysis of first unprovoked major VTE events (n = 602) demonstrated a significant reduction in recurrent VTE during the long-term preventative phase of treatment in the DOAC era (HR 0.296, 95 % CI: 0.097-0.901, p = 0.032) with no difference in clinically significantly bleeding rates (HR 0.529, 95 % CI 0.219-1.280, p = 0.158) between the eras.
Conclusion: Treatment outcomes for VTE appear to have improved over time with reduced rate of thrombotic and clinically significant bleeding complications in the DOAC era.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2022.09.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review.
Acta Haematol
December 2024
Hematology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- Managing cancer-associated thrombosis (CAT) poses challenges due to factors like bleeding risk, patient frailty, and drug interactions, necessitating careful treatment decisions.
- With the introduction of direct oral anticoagulants (DOACs), not all CAT patients benefit equally due to varied clinical and laboratory characteristics.
- This review discusses four specific scenarios in CAT management—brain metastasis, gastrointestinal malignancies, drug interactions, and thrombocytopenia—suggesting tailored treatment approaches based on current literature.
Article Synopsis
- A study in Japan compared outcomes of patients with venous thromboembolism (VTE) treated with warfarin (2010-2014) versus direct oral anticoagulants (DOACs) (2015-2020) from two multicenter registries.
- The use of DOACs skyrocketed from 2.6% in the warfarin era to 79% in the DOAC era, leading to a significant reduction in the 5-year recurrence rate of VTE (10.5% to 9.5%).
- However, the incidence of major bleeding remained similar between the two eras, indicating that while DOACs may reduce VTE recurrence, concerns about bleeding risks continue.
Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era.
Ann Vasc Surg
November 2024
Oregon Health & Science University, Portland, OR.
Background: Heparin-induced thrombocytopenia (HIT) is an uncommon complication of heparin therapy with significant risk for severe morbidity and mortality. We investigated the role and outcome of direct oral anticoagulants (DOACs) for the management of HIT.
Methods: After institutional review board (IRB) approval, a retrospective review was performed identifying all patients with positive HIT serotonin-release assays between 2020 and 2022 at two hospitals.
Trends in prior antithrombotic medication and risk of in-hospital mortality after spontaneous intracerebral hemorrhage: the J-ICH registry.
Sci Rep
May 2024
Department of Neurology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo, Tokyo, 113-8421, Japan.
Article Synopsis
- Spontaneous intracerebral hemorrhage (SICH) is a severe type of stroke, and prior use of warfarin significantly increases the risk of in-hospital mortality compared to not using any antithrombotics.
- The study analyzed 1,085 patients and found that while warfarin use was linked to higher mortality, the effects of direct oral anticoagulants (DOACs) were less clear and did not show a significant association with increased mortality.
- The findings suggest that additional measures are needed to address the risks of SICH in patients on oral anticoagulants, especially given that combining antiplatelets with warfarin sharply raises mortality rates.
Warfarin, not direct oral anticoagulants or antiplatelet therapy, is associated with increased bleeding risk in emergency general surgery patients: Implications in this new era of novel anticoagulants: An EAST multicenter study.
J Trauma Acute Care Surg
August 2024
From the Program in Trauma (M.G.), R Adams Cowley Shock Trauma Center, (S.P.A., L.O, A.Z.), University of Maryland; Department of Trauma Surgery (S.P.A., L.O., A.Z., M.G.) and Department of Epidemiology and Public Health (R.V.), University of Maryland Medical Center, Baltimore, Maryland; Department of Surgery, Mount Sinai South Nassau (J.N.B.), Oceanside, New York; Department of Surgery (A.C.), Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania; Department of Surgery (C.D., T.S.), UCHealth Memorial Hospital, Colorado Springs, Colorado; Department of Surgery (J.C.), Robert Wood Johnson Medical School, New Brunswick, New Jersey; Marshfield Clinic (D.C.), Marshfield, Wisconsin; Loma Linda University School of Medicine, Department of Surgery (R.D.C.), Loma Lina, California; Tufts Medical Center, Department of Surgery (N.B., M.L.), Tufts University School of Medicine, Boston, Massachusetts; Anne Arundel Medical Center, Department of Surgery (C.F.), Parole, Maryland; Memorial Health University Medical Center, Department of Surgery (K.M.), Savannah, Georgia; Brooke Army Medical Center, Department of Surgery (V.S.), Fort Sam Houston, Texas; Sidney Kimmel Medical College, Department of Surgery (P.S.L., S.O.), Thomas Jefferson University, Philadelphia, Pennsylvania; Department of Surgery (D.S.C.), Allina Health/Abbott Northwestern Hospital, Minneapolis, Minnesota; Department of Surgery (J.P., S.M.), Northwestern University, Evanston, Illinois; Department of Surgery (J.E.), George Washington University, Washington, DC; Columbia University Irving Medical Center, Department of Surgery (B.H., N.C.), New York, New York; Cooper University (A.G.-S.), Camden, New Jersey; University of California Irvine Medical Center, Department of Surgery (J.N., K.R.), Irvine, California; McLaren Oakland Hospital, Department of Surgery (J.P., L.B.), Pontiac, Michigan; Sanford Health, Department of Surgery (L.H.), Sioux Falls, South Dakota; University of Kentucky Medical Center, Department of Surgery (J.R.), Lexington, Kentucky; Methodist Medical Center, Department of Surgery (M.T.), Dallas, Texas.
Introduction: This study aimed to assess perioperative bleeding complications and in-hospital mortality in patients requiring emergency general surgery presenting with a history of antiplatelet (AP) versus direct oral anticoagulant (DOAC) versus warfarin use.
Methods: A prospective observational study across 21 centers between 2019 and 2022 was conducted. Inclusion criteria were age 18 years or older, and DOAC, warfarin, or AP use within 24 hours of an emergency general surgery procedure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!